Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study

In clinical practice, 25–30% of the patients treated with fluoropyrimidines experience severe fluoropyrimidine‐related toxicity. Extensively clinically validated DPYD genotyping tests are available to identify patients at risk of severe toxicity due to decreased activity of dihydropyrimidine dehydro...

Descripción completa

Detalles Bibliográficos
Autores principales: de With, Mirjam, Knikman, Jonathan, de Man, Femke M., Lunenburg, Carin A. T. C., Henricks, Linda M., van Kuilenburg, André B. P., Maring, Jan G., van Staveren, Maurice C., de Vries, Niels, Rosing, Hilde, Beijnen, Jos H., Pluim, Dick, Modak, Anil, Imholz, Alex L. T., van Schaik, Ron H. N., Schellens, Jan H. M., Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk‐Jan, Mathijssen, Ron H. J., Swen, Jesse J., Meulendijks, Didier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322339/
https://www.ncbi.nlm.nih.gov/pubmed/35397172
http://dx.doi.org/10.1002/cpt.2608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322339/
https://www.ncbi.nlm.nih.gov/pubmed/35397172
http://dx.doi.org/10.1002/cpt.2608

Ejemplares similares